• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Meridian Bioscience Inc. (Amendment)

    2/9/23 11:27:43 AM ET
    $VIVO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $VIVO alert in real time by email
    SC 13G/A 1 tv01407-meridianbiosciencein.htm SCHEDULE 13G/A meridianbioscienceinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 13)*

    Name of issuer:  Meridian Bioscience Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  589584101

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  589584101

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    72,566

    7.  SOLE DISPOSITIVE POWER

    4,859,976

    8.  SHARED DISPOSITIVE POWER

    110,129

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,970,105

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    11.34%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Meridian Bioscience Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    3471 River Hills Drive
    Cincinnati, OH 45244

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    589584101

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $VIVO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VIVO

    DatePrice TargetRatingAnalyst
    2/7/2022$28.00 → $30.00Buy
    HC Wainwright & Co.
    11/15/2021$27.00 → $28.00Buy
    HC Wainwright & Co.
    8/9/2021$30.00 → $27.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $VIVO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • December 10, 2021 - Coronavirus (COVID-19) Update: December 10, 2021

      For Immediate Release: December 10, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On December 9, 2021, the FDA updated the SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests web page to share the latest information. The update added new information about the Meridian Bioscience, Inc. Revogene SARS-CoV-2 test, inc

      12/10/21 1:56:40 PM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VIVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Meridian Bioscience Inc. (Amendment)

      SC 13G/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)

      2/9/23 11:27:43 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13D/A filed by Meridian Bioscience Inc. (Amendment)

      SC 13D/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)

      2/3/23 2:06:19 PM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Meridian Bioscience Inc. (Amendment)

      SC 13G/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)

      1/31/23 11:06:04 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VIVO
    Financials

    Live finance-specific insights

    See more
    • Meridian Bioscience, Inc. Enters into Agreement to Be Acquired by SD Biosensor and SJL Partners in $1.53 Billion All-Cash Transaction

      Shareholders to Receive $34.00 Per Share in Cash, Providing Immediate, Compelling and Certain Value Transaction Follows Deliberate Review, Including Outreach to Potential Strategic and Financial Partners CINCINNATI and SEOUL, South Korea, July 7, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biosensor, Inc. ("SDB") (KOSE: A137310) and SJL Partners LLC ("SJL") (collectively, the "Consortium") announced today that they have entered into a definitive merger agreement whereby a newly formed affiliate vehicle of the Consortium will acquire Meridian in an a

      7/7/22 7:17:00 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • MERIDIAN BIOSCIENCE REPORTS RECORD SECOND QUARTER FISCAL 2022 OPERATING RESULTS

      CINCINNATI, May 6, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced financial results for the second quarter ended March 31, 2022. Second Quarter Fiscal 2022 Highlights (Comparison to Second Quarter Fiscal 2021): Consolidated net revenues totaled $111.2 million, the highest in Company history, with both segments ahead of expectationsLife Science segment delivered record net revenues of $70.1 millionDiagnostics segment net revenues increased 29% year-over-year to a record $41.1 millionLaunched Lyo-Ready™ sample specific master mixes for bloodResumed

      5/6/22 8:00:00 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Meridian Acquires EUPROTEIN to Further Expand Recombinant Protein Capabilities

      CINCINNATI, Ohio, May 2, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has acquired, through its subsidiary Meridian Life Science, Inc., substantially all of the assets of EUPROTEIN Inc.  The transaction closed on April 30, 2022. EUPROTEIN Inc. offers custom development and production of high-quality bioresearch reagents, with a particular focus on human and other mammalian proteins and recombinant monoclonal antibodies.  This acquisition will help

      5/2/22 8:47:00 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VIVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Meridian Bioscience with a new price target

      HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $30.00 from $28.00 previously

      2/7/22 6:13:53 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • HC Wainwright & Co. reiterated coverage on Meridian Bioscience with a new price target

      HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $28.00 from $27.00 previously

      11/15/21 6:32:31 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • HC Wainwright & Co. reiterated coverage on Meridian Bioscience with a new price target

      HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $27.00 from $30.00 previously

      8/9/21 6:33:26 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VIVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Williams Felicia returned 10,274 shares to the company, closing all direct ownership in the company

      4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)

      1/31/23 2:22:23 PM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4: Sazdanoff Catherine returned 16,424 shares to the company, closing all direct ownership in the company

      4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)

      1/31/23 2:21:33 PM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4: Rice John Mccune Jr. returned 27,449 shares to the company, closing all direct ownership in the company

      4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)

      1/31/23 2:20:26 PM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VIVO
    Leadership Updates

    Live Leadership Updates

    See more
    • Meridian Bioscience Announces Retirement of CFO Bryan Baldasare

      CINCINNATI, Dec. 2, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Bryan Baldasare, Executive Vice President, Chief Financial Officer, and Secretary, will retire from Meridian effective December 31, 2021.  The Company is engaging an executive search firm in the recruitment of a new chief financial officer.  The Company appointed Julie Smith to the position of Senior Vice President, Controller, effective December 6, 2021, and principal accounting officer, effective January 1, 2022.

      12/2/21 8:00:00 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Meridian Bioscience Announces Retirement of Chairman David Phillips

      CINCINNATI, Nov. 24, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that David Phillips, Chairman of the Board of Directors, will retire from the Board of Directors and not seek re-election when his term ends in January 2022.  The Board of Directors will elect a new chair when Mr. Phillips' term expires and will not replace the vacated seat, which will reduce the number of directors to eight. Mr. Phillips joined the Meridian Board of Directors in 2000 and ha

      11/24/21 9:05:00 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VIVO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SD Biosensor and SJL Partners Complete Transaction to Acquire Meridian Bioscience

      CINCINNATI and SEOUL, South Korea, Jan. 31, 2023 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biosensor, Inc. ("SDB") (KOSE: A137310) and SJL Partners LLC ("SJL") (collectively, the "Consortium"), announced today that they have completed the transaction to acquire Meridian. Under the terms of the merger, Meridian shareholders have the right to receive $34.00 per share in cash. Meridian stock will no longer be traded on the NASDAQ Global Select Market. Meridian will cont

      1/31/23 1:56:00 PM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • DoubleVerify Holdings to Join S&P SmallCap 600

      NEW YORK, Jan. 25, 2023 /PRNewswire/ -- DoubleVerify Holdings Inc. (NYSE:DV) will replace Meridian Bioscience Inc. (NASD: VIVO) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, January 31. SD Biosensor is acquiring Meridian Bioscience in a deal expected to be completed soon pending final conditions. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector January 31, 2023 S&P SmallCap 600 Addition DoubleVerify Holdings DV Inf

      1/25/23 5:58:00 PM ET
      $DV
      $SPGI
      $VIVO
      Computer Software: Programming Data Processing
      Technology
      Finance: Consumer Services
      Finance
    • Meridian Bioscience Announces Anticipated Closing Date of the Pending Merger

      CINCINNATI, Dec. 12, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced that it has entered into a side letter with the buyer, setting the closing date of Meridian's pending merger for January 31, 2023. As previously disclosed, on July 7, 2022, Meridian, entered into an Agreement and Plan of Merger (the "Merger Agreement") with SD Biosensor, Inc., ("SDB"), Columbus Holding Company ("Parent"), and Madeira Acquisition Corp., a direct wholly owned subsidiary of Parent ("

      12/12/22 8:00:00 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VIVO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Meridian Bioscience Inc.

      15-12G - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)

      2/13/23 4:31:51 PM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 10-Q filed by Meridian Bioscience Inc.

      10-Q - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)

      2/9/23 8:23:24 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form EFFECT filed by Meridian Bioscience Inc.

      EFFECT - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)

      2/6/23 12:15:16 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care